Abstract: Objective: To investigate whether antinuclear antibody (ANA), anticardiolipin antibody (aCL) and anti-β2-glycoprotein1 antibody (aβ2GP1) can be used as the screening markers in non-elderly patients with diminished ovarian reserve (DOR) before their IVF/ICSI treatment. Methods：From January 2018 to April 2019, 127 non-elderly DOR patients (non-elderly DOR group, 127 cases) and 82 women who were planned to undertake IVF/ICSI treatment due to male factors (control group, 82 cases) were collected as the subjects. Sera ANA was detected by immunofluorescence, aCL and aβ2GP1 antibodies were detected by enzyme-linked immunosorbent assay. Results：The total positive rate of at least one of the three antibodies in the non-elderly DOR group (24.41%, 31/127) was significantly higher than that in the control group (12.20%, 10/82), the difference was statistically significant (P＜0.05). The total positive rate of ANA in the non-elderly DOR group (3.15%, 4/127) was slightly higher than that in the control group (1.22%, 1/82), the difference was not statistically significant (P＞0.05). The difference of the total positive rate of aCL was not significant between the non-elderly DOR group (8.66%, 11/127) and the control group (6.10%, 5/82) (P＞0.05). The total positive rate of aβ2GP1 in the non-elderly DOR group (15.75%, 20/127) was significantly higher than that in the control group (6.10%, 5/82), the difference was statistically significant (P＜0.05). Conclusions：The combined screening of serum ANA, aCL and aβ2GP1 can be recommended for non-elderly patients with diminished ovarian reserve before IVF/ICSI treatment. 

Key words: Antibodies, antinuclear；, Antibodies, anticardiolipin；, Anti-β2-glycoprotein 1 antibody；, Diminished ovarian reserve；, Enzyme-linked immunosorbent assay；, Fluoroimmunoassay